The FDA's approval of Alnylam's heart disease drug expands treatment options in a market poised for growth. Meanwhile, the ...

Over the years, there has been an increasing demand for an effective and cost-efficient drug discovery process. The study of ...

The Sunrise Centre, a drug and alcohol addiction treatment and recovery center in Alpena, is waiting on approval for a loan ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Lawyers inside and outside the US Securities and Exchange Commission (SEC) have speculated that the agency’s new leadership will take a ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

People with severe asthma insured by BlueCross BlueShield of Illinois may soon face a new hurdle in accessing a treatment ...

A patient with a rare illness would have died if it weren't for AI-powered drug repurposing: When side effects come to the ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...